MA33517B1 - Analogues acylés du glucagon - Google Patents
Analogues acylés du glucagonInfo
- Publication number
- MA33517B1 MA33517B1 MA34615A MA34615A MA33517B1 MA 33517 B1 MA33517 B1 MA 33517B1 MA 34615 A MA34615 A MA 34615A MA 34615 A MA34615 A MA 34615A MA 33517 B1 MA33517 B1 MA 33517B1
- Authority
- MA
- Morocco
- Prior art keywords
- glucagon
- acel
- methods
- relates
- peptides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L'invention porte sur des matériaux et sur des procédés pour favoriser la perte de poids ou pour prévenir la prise de poids, et pour traiter le diabète et les troubles métaboliques associés. En particulier, l'invention porte sur de nouveaux peptides analogues acylés du glucagon efficaces dans le cadre desdits procédés. Les peptides peuvent médier leur effet en ayant une sélectivité accrue pour le récepteur GLP-1 par comparaison au glucagon humain.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22508009P | 2009-07-13 | 2009-07-13 | |
EP09251780 | 2009-07-13 | ||
EP10157240 | 2010-03-22 | ||
DKPA201000412 | 2010-05-10 | ||
PCT/DK2010/000099 WO2011006497A1 (fr) | 2009-07-13 | 2010-06-24 | Analogues acylés du glucagon |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33517B1 true MA33517B1 (fr) | 2012-08-01 |
Family
ID=43448959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34615A MA33517B1 (fr) | 2009-07-13 | 2012-02-08 | Analogues acylés du glucagon |
Country Status (30)
Country | Link |
---|---|
US (3) | US9156901B2 (fr) |
EP (1) | EP2454282B1 (fr) |
JP (1) | JP6054742B2 (fr) |
KR (1) | KR101809024B1 (fr) |
CN (2) | CN104961822A (fr) |
AP (1) | AP3329A (fr) |
AU (1) | AU2010272944B2 (fr) |
CA (1) | CA2767792A1 (fr) |
DK (1) | DK2454282T3 (fr) |
EA (1) | EA022816B1 (fr) |
EC (1) | ECSP12011593A (fr) |
ES (1) | ES2537287T3 (fr) |
GE (1) | GEP20146056B (fr) |
HK (1) | HK1171035A1 (fr) |
HR (1) | HRP20150557T1 (fr) |
HU (1) | HUE026255T2 (fr) |
IL (1) | IL217150A0 (fr) |
MA (1) | MA33517B1 (fr) |
ME (1) | ME02220B (fr) |
MX (1) | MX2012000564A (fr) |
MY (1) | MY188182A (fr) |
NZ (1) | NZ597981A (fr) |
PE (1) | PE20121130A1 (fr) |
PL (1) | PL2454282T3 (fr) |
PT (1) | PT2454282E (fr) |
RS (1) | RS53987B1 (fr) |
SG (1) | SG177609A1 (fr) |
SI (1) | SI2454282T1 (fr) |
UA (1) | UA104766C2 (fr) |
WO (1) | WO2011006497A1 (fr) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2799447B1 (fr) | 2008-12-15 | 2016-11-23 | Zealand Pharma A/S | Analogues de glucagon |
AU2008365559B2 (en) | 2008-12-15 | 2016-02-25 | Zealand Pharma A/S | Glucagon analogues |
CN102292347A (zh) | 2008-12-15 | 2011-12-21 | 西兰制药公司 | 胰高血糖素类似物 |
KR20110126591A (ko) | 2008-12-15 | 2011-11-23 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
HUE026255T2 (en) | 2009-07-13 | 2016-06-28 | Zealand Pharma As | Acylated glucagon analogues |
UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
CA2802897A1 (fr) | 2010-06-24 | 2011-12-29 | Zealand Pharma A/S | Analogues de glucagon |
PE20140969A1 (es) * | 2011-01-20 | 2014-07-24 | Zealand Pharma As | Combinacion de analogos del glucagon acilados con analogos de insulina |
WO2012150503A2 (fr) | 2011-05-03 | 2012-11-08 | Zealand Pharma A/S | Composés sélectifs de la signalisation d'agoniste mixte glu-glp-1 |
WO2012153196A2 (fr) | 2011-05-10 | 2012-11-15 | Zealand Pharma A/S | Composés sélectifs pour une signalisation d'agonistes doubles de glu-glp1 |
SG10201604564XA (en) | 2011-06-10 | 2016-07-28 | Hanmi Science Co Ltd | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |
AU2012270366C1 (en) | 2011-06-17 | 2017-07-13 | Hanmi Science Co., Ltd. | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
AR088161A1 (es) | 2011-09-23 | 2014-05-14 | Novo Nordisk As | Analogos de glucagon |
KR20140114845A (ko) * | 2011-12-23 | 2014-09-29 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
IN2014MN02304A (fr) | 2012-05-03 | 2015-08-07 | Zealand Pharma As | |
EP2664374A1 (fr) * | 2012-05-15 | 2013-11-20 | F. Hoffmann-La Roche AG | Dérivés de dipeptide d'acide lysine-glutamique |
JP2015525226A (ja) | 2012-06-14 | 2015-09-03 | サノフイ | エキセンディン−4ペプチドアナログ |
CN104662038B (zh) | 2012-07-23 | 2018-11-06 | 西兰制药公司 | 胰高血糖素类似物 |
KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
TWI608013B (zh) * | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
WO2014049610A2 (fr) | 2012-09-26 | 2014-04-03 | Cadila Healthcare Limited | Peptides en tant que triples agonistes des récepteurs de gip, glp-1 et glucagon |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
KR102311517B1 (ko) | 2012-11-06 | 2021-10-14 | 한미약품 주식회사 | 옥신토모듈린과 면역글로불린 단편을 포함하는 단백질 결합체의 액상 제제 |
KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
US11065304B2 (en) | 2012-11-20 | 2021-07-20 | Mederis Diabetes, Llc | Peptide pharmaceuticals for insulin resistance |
ES2653765T3 (es) | 2012-12-21 | 2018-02-08 | Sanofi | Agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón |
EP2968581A1 (fr) * | 2013-03-14 | 2016-01-20 | Medimmune Limited | Co-agonistes pégylés du glucagon et de glp-1 pour le traitement de l'obésité |
ES2624961T3 (es) | 2013-03-21 | 2017-07-18 | Sanofi-Aventis Deutschland Gmbh | Síntesis de productos de péptido que contienen imida cíclica |
CN105189465B (zh) | 2013-03-21 | 2019-02-26 | 赛诺菲-安万特德国有限公司 | 合成含有乙内酰脲的肽产物 |
AR095986A1 (es) | 2013-04-03 | 2015-11-25 | Sanofi Sa | Proteínas modificadas que regulan glucosa en sangre con perfil alterado de actividad farmacológica y preparación de las mismas |
MX362275B (es) | 2013-04-18 | 2019-01-10 | Novo Nordisk As | Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico. |
GB201315335D0 (en) | 2013-08-29 | 2013-10-09 | Of Singapore | Amino diacids containing peptide modifiers |
EP3057984B1 (fr) | 2013-10-17 | 2018-07-11 | Zealand Pharma A/S | Analogues de glucagon acylés |
US9988429B2 (en) * | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
TR201902516T4 (tr) | 2013-11-06 | 2019-03-21 | Zealand Pharma As | Glukagon-glp-1-gıp üçlü agonist bileşikleri. |
CN105849122B (zh) * | 2013-11-06 | 2021-04-30 | 西兰制药公司 | Gip-glp-1双重激动剂化合物及方法 |
TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽-4(exendin-4)胜肽類似物 |
TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物 |
WO2015086729A1 (fr) | 2013-12-13 | 2015-06-18 | Sanofi | Agonistes mixtes des récepteurs glp-1/gip |
WO2015086731A1 (fr) | 2013-12-13 | 2015-06-18 | Sanofi | Analogues peptidiques de l'exendine-4 en tant qu'agonistes mixtes des récepteurs glp-1/glucagon |
EP3080149A1 (fr) | 2013-12-13 | 2016-10-19 | Sanofi | Agonistes mixtes des récepteurs du glp-1/glucagon |
AR098616A1 (es) | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Péptido para el tratamiento de hipoglicemia severa |
RU2016134425A (ru) * | 2014-02-18 | 2018-03-20 | Ново Нордиск А/С | Стабильные аналоги глюкагона и их применение для лечения гипогликемии |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
MX371033B (es) | 2014-05-28 | 2020-01-13 | Mederis Diabetes Llc | Productos farmacéuticos mejorados de péptido para resistencia a la insulina. |
US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
TWI802396B (zh) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
CN104926934B (zh) * | 2014-09-23 | 2016-11-09 | 蒋先兴 | 胃泌酸调节素类似物 |
EP3212218B1 (fr) | 2014-10-29 | 2021-06-30 | Zealand Pharma A/S | Composés agonistes de gip et procédés associés |
PE20230304A1 (es) | 2014-12-30 | 2023-02-13 | Hanmi Pharm Ind Co Ltd | Derivados de glucagon como agentes hipoglucemicos y antiobesidad |
KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
EP3673899A1 (fr) | 2015-02-17 | 2020-07-01 | Eli Lilly And Co. | Formulation de poudre nasale pour le traitement de l'hypoglycémie |
WO2016146739A1 (fr) | 2015-03-18 | 2016-09-22 | Zealand Pharma A/S | Analogues d'amyline |
WO2016168388A2 (fr) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Thérapies pour l'obésité, le diabète et indications associées |
ES2763329T3 (es) | 2015-04-16 | 2020-05-28 | Zealand Pharma As | Análogo de glucagón acilado |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
WO2016198628A1 (fr) | 2015-06-12 | 2016-12-15 | Sanofi | Dérivés d'exendine-4 non-acylée comme agonistes doubles du récepteur glp -1/glucagon |
WO2016198624A1 (fr) | 2015-06-12 | 2016-12-15 | Sanofi | Dérivés d'exendine 4 utilisés en tant qu'agonistes trigonaux des récepteurs du glp-1/glucagon/gip |
AR105485A1 (es) | 2015-06-30 | 2017-10-11 | Hanmi Pharm Ind Co Ltd | Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo |
AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
CR20180380A (es) | 2015-12-31 | 2018-12-07 | Hanmi Pharm Ind Co Ltd | Agosnista triple de receptores de glucagón/glp-1/gip |
SG10202109721PA (en) | 2016-03-10 | 2021-10-28 | Medimmune Ltd | Glucagon and glp-1 co-agonists for the treatment of obesity |
CN106084031B (zh) * | 2016-06-02 | 2020-03-31 | 中国药科大学 | 一类glp-1r/gcgr双重激动剂在用于降糖和减肥药物中的运用 |
CN105968186B (zh) * | 2016-06-02 | 2020-10-30 | 中国药科大学 | 具有长效化作用的胰高血糖素(Glu)类似物及其应用 |
US11179444B2 (en) | 2016-06-09 | 2021-11-23 | Amidebio, Llc | Glucagon analogs and methods of use thereof |
BR112018077457A2 (pt) | 2016-06-29 | 2019-04-02 | Hanmi Pharm. Co., Ltd. | composição farmacêutica para evitar ou tratar hiperinsulinismo congênito e seu método, hipoglicemia e seu método, síndrome metabólica e seu método e peptídeo isolado |
AU2017307033B2 (en) | 2016-08-05 | 2020-11-26 | Boehringer Ingelheim International Gmbh | Oxadiazolopyridine derivates for use as ghrelin O-acyl transferase (GOAT) inhibitors |
TWI784968B (zh) | 2016-09-09 | 2022-12-01 | 丹麥商西蘭製藥公司 | 澱粉素類似物 |
JOP20190097A1 (ar) | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | الجلوبولينات المناعية واستخداماتها |
TW201832783A (zh) | 2016-12-02 | 2018-09-16 | 法商賽諾菲公司 | 包含glp-1/胰高血糖素雙重激動劑、連接子和透明質酸的接合物 |
PE20191083A1 (es) * | 2016-12-09 | 2019-08-20 | Zealand Pharma As | Agonistas duales acilados de glp-1/glp-2 |
WO2018104558A1 (fr) * | 2016-12-09 | 2018-06-14 | Zealand Pharma A/S | Agonistes doubles de glp-1/glp-2 acylés |
JP2020500890A (ja) * | 2016-12-09 | 2020-01-16 | ジーランド・ファーマ・ア/エス | Glp−1/glp−2二重アゴニスト |
SG11202006300XA (en) | 2018-02-02 | 2020-07-29 | Boehringer Ingelheim Int | Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
EP3746451B1 (fr) | 2018-02-02 | 2023-07-12 | Boehringer Ingelheim International GmbH | Dérivés d'oxadiazolopyridine à substitution benzyle, (pyridin-3-yl)méthyle ou (pyridin-4-yl)méthyle utilisés en tant qu'inhibiteurs de la ghréline o-acyltransférase (goat) |
US11136337B2 (en) | 2018-02-02 | 2021-10-05 | Boehringer Ingelheim International Gmbh | Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors |
CR20200329A (es) | 2018-02-02 | 2020-09-04 | Boehringer Ingelheim Int | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-acil transferasa (goat) |
CN110317258B (zh) * | 2018-03-29 | 2023-03-17 | 齐鲁制药有限公司 | 一种索玛鲁肽的新多肽片段及其制备方法 |
US10875902B2 (en) | 2018-04-25 | 2020-12-29 | Janssen Pharmaceutica Nv | Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof |
TW202024134A (zh) | 2018-12-21 | 2020-07-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 雙特異性蛋白 |
TWI771669B (zh) | 2019-04-26 | 2022-07-21 | 美商美國禮來大藥廠 | 製備穩定胜肽調配物之方法 |
AU2020384729A1 (en) | 2019-11-11 | 2022-04-14 | Boehringer Ingelheim International Gmbh | NPY2 receptor agonists |
WO2021233884A1 (fr) | 2020-05-22 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Procédé continu de fabrication de 7-amino-5-méthyl-[1,2,5] oxadiazolo [3,4-b] pyridine-carboxylate d'alkyle |
EP4153599B1 (fr) | 2020-05-22 | 2024-03-13 | Boehringer Ingelheim International GmbH | Procédé de fabrication de 7-amino-5-méthyl- [1,2,5] oxadiazolo [3,4-b] pyridine-carboxylate d'alkyle |
BR112022025623A2 (pt) | 2020-08-07 | 2023-03-07 | Boehringer Ingelheim Int | Agonistas solúveis de receptores de npy2 |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ202757A (en) | 1981-12-23 | 1985-11-08 | Novo Industri As | Peptides and medicaments |
CA2468374C (fr) | 1996-08-30 | 2010-12-21 | Novo-Nordisk A/S | Derives de glp-1 |
IL128828A0 (en) | 1996-09-09 | 2000-01-31 | Zealand Pharmaceuticals As | Peptide prodrugs containing an alpha-hydroxy acid linker |
ES2239364T3 (es) | 1996-09-09 | 2005-09-16 | Zealand Pharma A/S | Sintesis de peptidos en fase solida. |
EP1066314B1 (fr) | 1997-11-14 | 2007-12-26 | Amylin Pharmaceuticals, Inc. | Nouveaux composes agonistes de l'exendine |
EP1062229A1 (fr) | 1998-03-09 | 2000-12-27 | Zealand Pharmaceuticals A/S | Conjugues peptidiques pharmacologiquement actifs ayant une tendance reduite a l'hydrolyse enzymatique |
CA2353574C (fr) | 1998-12-07 | 2012-05-08 | Zheng Xin Dong | Analogues du glp-1 |
US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
CN1344248A (zh) | 1999-03-17 | 2002-04-10 | 诺沃挪第克公司 | 肽的酰化方法和新酰化剂 |
EP1076066A1 (fr) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides abaissant le taux de glucose sanguin |
SI1695983T1 (sl) | 2000-06-16 | 2009-08-31 | Lilly Co Eli | Analogi glukagonu podobnega peptida-1 |
GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
AU2002346491A1 (en) | 2001-12-19 | 2003-07-09 | Eli Lilly And Company | Crystalline compositions for controlling blood glucose |
KR20040070237A (ko) | 2001-12-20 | 2004-08-06 | 일라이 릴리 앤드 캄파니 | 연장된 작용 시간을 갖는 인슐린 분자 |
GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
US20060217290A1 (en) | 2003-04-29 | 2006-09-28 | Kohn Wayne D | Insulin analogs having protracted time action |
CA2586771A1 (fr) | 2004-11-12 | 2006-05-18 | Novo Nordisk A/S | Formulations stables de peptides |
TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
CA2607566A1 (fr) | 2005-05-06 | 2006-11-16 | Bayer Pharmaceuticals Corporation | Agonistes vis-a-vis du recepteur peptidique de type glucagon 1 (glp-1) et procedes pharmacologiques d'utilisation |
BRPI0612069A2 (pt) | 2005-06-13 | 2009-01-20 | Imp Innovations Ltd | compostos e seus efeitos sobre o comportamento de alimentaÇço |
US20090202497A1 (en) | 2005-08-23 | 2009-08-13 | The General Hospital Corporation | Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes |
WO2007056362A2 (fr) | 2005-11-07 | 2007-05-18 | Indiana University Research And Technology Corporation | Analogues de glucagon a solubilite et a stabilite physiologiques ameliorees |
WO2007081824A2 (fr) | 2006-01-06 | 2007-07-19 | Case Western Reserve University | Protéines résistantes à la fibrillation |
US7928058B2 (en) | 2006-02-22 | 2011-04-19 | Merck Sharp & Dohme Corp. | Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition |
BRPI0714871A2 (pt) | 2006-07-18 | 2013-05-07 | Sanofi Aventis | anticorpo antagonista para o tratamento de cÂncer |
ITMI20061607A1 (it) | 2006-08-09 | 2008-02-10 | Maria Vincenza Carriero | Peptidi con attivita farmacologica |
EP2074140B8 (fr) | 2006-10-04 | 2015-10-28 | Case Western Reserve University | Insuline et analogues de l'insuline résistants à la fibrillation |
TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
EP2487184A1 (fr) | 2007-02-15 | 2012-08-15 | Indiana University Research and Technology Corporation | Co-agonistes du récepteur de glucagon/GLP-1 |
EP2025684A1 (fr) | 2007-08-15 | 2009-02-18 | Zealand Pharma A/S | Analogues du glucagon |
EP2158214B1 (fr) | 2007-06-15 | 2011-08-17 | Zealand Pharma A/S | Analogues du glucagon |
JP5547083B2 (ja) | 2007-11-20 | 2014-07-09 | アンブルックス,インコーポレイテッド | 修飾されたインスリンポリペプチドおよびそれらの使用 |
DE102008003566A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
KR20100111683A (ko) | 2008-01-09 | 2010-10-15 | 사노피-아벤티스 도이칠란트 게엠베하 | 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체 |
DE102008003568A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
RU2524423C2 (ru) | 2008-01-09 | 2014-07-27 | Санофи-Авентис Дойчланд Гмбх | Новые производные инсулина с чрезвычайно замедленным профилем время/действие |
US8993516B2 (en) | 2008-04-14 | 2015-03-31 | Case Western Reserve University | Meal-time insulin analogues of enhanced stability |
AU2009240636A1 (en) | 2008-04-22 | 2009-10-29 | Case Western Reserve University | Isoform-specific insulin analogues |
TWI451876B (zh) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
CL2009001424A1 (es) | 2008-06-17 | 2010-04-30 | Univ Indiana Res & Tech Corp | Peptido tipo glucagon; dimero que comprende dos de dichos peptidos; composicion farmaceutica que lo comprende; y su uso para tratar diabetes o inducir perdida de peso. |
AU2009260301B2 (en) | 2008-06-17 | 2015-09-03 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers |
US9062124B2 (en) | 2008-06-17 | 2015-06-23 | Indiana University Research And Technology Corporation | GIP-based mixed agonists for treatment of metabolic disorders and obesity |
PL219335B1 (pl) | 2008-07-04 | 2015-04-30 | Inst Biotechnologii I Antybiotyków | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna |
MX2011001181A (es) | 2008-07-31 | 2011-04-05 | Univ Case Western Reserve | Insulina estabilizada con halogeno. |
WO2010016940A2 (fr) | 2008-08-07 | 2010-02-11 | Ipsen Pharma S.A.S. | Analogues de polypeptide insulinotrope glucose-dépendant |
ES2561208T3 (es) | 2008-09-12 | 2016-02-25 | Novo Nordisk A/S | Método de acilación de un péptido o una proteína |
AU2008365559B2 (en) | 2008-12-15 | 2016-02-25 | Zealand Pharma A/S | Glucagon analogues |
KR20110126591A (ko) | 2008-12-15 | 2011-11-23 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
EP2799447B1 (fr) | 2008-12-15 | 2016-11-23 | Zealand Pharma A/S | Analogues de glucagon |
CN102292347A (zh) | 2008-12-15 | 2011-12-21 | 西兰制药公司 | 胰高血糖素类似物 |
CA2747490C (fr) | 2008-12-19 | 2017-02-14 | Indiana University Research And Technology Corporation | Analogues d'insuline |
WO2010080609A1 (fr) | 2008-12-19 | 2010-07-15 | Indiana University Research And Technology Corporation | Promédicaments insuliniques à base d'amide |
WO2010096052A1 (fr) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Analogues d'oxyntomoduline |
US20100240883A1 (en) | 2009-03-18 | 2010-09-23 | Nian Wu | Lipid-drug conjugates for drug delivery |
CN101519446A (zh) | 2009-03-31 | 2009-09-02 | 上海一就生物医药有限公司 | 一种重组人胰岛素及其类似物的制备方法 |
CA2765026A1 (fr) | 2009-06-16 | 2010-12-23 | Indiana University Research And Technology Corporation | Composes de glucagon actifs sur le recepteur gip |
HUE026255T2 (en) | 2009-07-13 | 2016-06-28 | Zealand Pharma As | Acylated glucagon analogues |
CN111560060A (zh) | 2009-12-16 | 2020-08-21 | 诺沃—诺迪斯克有限公司 | 双酰化glp-1衍生物 |
EP2525809B1 (fr) | 2010-01-20 | 2016-08-03 | Zealand Pharma A/S | Glucagon-glp1 agonistes doubles pour le traitement des maladies cardiaques |
BR112012018585A2 (pt) | 2010-01-27 | 2017-01-10 | Univ Indiana Res & Tech Corp | conjungados e composições de glucagon antagonista-gip agonista para o tratamento de distúrbios metabólicos e de obesidade |
AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
US20130053310A1 (en) | 2010-03-26 | 2013-02-28 | Novo Nordisk A/S | Novel glucagon analogues |
WO2011134284A1 (fr) | 2010-04-27 | 2011-11-03 | 浙江贝达药业有限公司 | Analogue du glp-1 et ses applications |
UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
CA2802897A1 (fr) | 2010-06-24 | 2011-12-29 | Zealand Pharma A/S | Analogues de glucagon |
US9708383B2 (en) | 2010-11-09 | 2017-07-18 | Novo Nordisk A/S | Double-acylated GLP-1 derivatives |
PE20140969A1 (es) | 2011-01-20 | 2014-07-24 | Zealand Pharma As | Combinacion de analogos del glucagon acilados con analogos de insulina |
KR20140020292A (ko) | 2011-03-28 | 2014-02-18 | 노보 노르디스크 에이/에스 | 신규 글루카곤 유사체 |
JP6022538B2 (ja) | 2011-04-12 | 2016-11-09 | ノヴォ ノルディスク アー/エス | 二重アシル化されたglp−1誘導体 |
WO2012150503A2 (fr) | 2011-05-03 | 2012-11-08 | Zealand Pharma A/S | Composés sélectifs de la signalisation d'agoniste mixte glu-glp-1 |
WO2012153196A2 (fr) | 2011-05-10 | 2012-11-15 | Zealand Pharma A/S | Composés sélectifs pour une signalisation d'agonistes doubles de glu-glp1 |
CN103764673A (zh) | 2011-06-10 | 2014-04-30 | 北京韩美药品有限公司 | 葡萄糖依赖性促胰岛素多肽类似物、其药物组合物及应用 |
AR088161A1 (es) | 2011-09-23 | 2014-05-14 | Novo Nordisk As | Analogos de glucagon |
KR20140114845A (ko) | 2011-12-23 | 2014-09-29 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
IN2014MN02304A (fr) | 2012-05-03 | 2015-08-07 | Zealand Pharma As | |
CN104662038B (zh) | 2012-07-23 | 2018-11-06 | 西兰制药公司 | 胰高血糖素类似物 |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
EP3057984B1 (fr) | 2013-10-17 | 2018-07-11 | Zealand Pharma A/S | Analogues de glucagon acylés |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
CN105849122B (zh) | 2013-11-06 | 2021-04-30 | 西兰制药公司 | Gip-glp-1双重激动剂化合物及方法 |
RU2016134425A (ru) | 2014-02-18 | 2018-03-20 | Ново Нордиск А/С | Стабильные аналоги глюкагона и их применение для лечения гипогликемии |
ES2763329T3 (es) | 2015-04-16 | 2020-05-28 | Zealand Pharma As | Análogo de glucagón acilado |
-
2010
- 2010-06-24 HU HUE10737252A patent/HUE026255T2/en unknown
- 2010-06-24 UA UAA201201419A patent/UA104766C2/uk unknown
- 2010-06-24 ME MEP-2015-72A patent/ME02220B/me unknown
- 2010-06-24 AP AP2012006107A patent/AP3329A/xx active
- 2010-06-24 WO PCT/DK2010/000099 patent/WO2011006497A1/fr active Application Filing
- 2010-06-24 CN CN201510319285.XA patent/CN104961822A/zh active Pending
- 2010-06-24 PL PL10737252T patent/PL2454282T3/pl unknown
- 2010-06-24 NZ NZ597981A patent/NZ597981A/en not_active IP Right Cessation
- 2010-06-24 MX MX2012000564A patent/MX2012000564A/es active IP Right Grant
- 2010-06-24 ES ES10737252.6T patent/ES2537287T3/es active Active
- 2010-06-24 SI SI201030922T patent/SI2454282T1/sl unknown
- 2010-06-24 PT PT107372526T patent/PT2454282E/pt unknown
- 2010-06-24 US US13/383,783 patent/US9156901B2/en not_active Expired - Fee Related
- 2010-06-24 JP JP2012519884A patent/JP6054742B2/ja not_active Expired - Fee Related
- 2010-06-24 CA CA2767792A patent/CA2767792A1/fr not_active Abandoned
- 2010-06-24 KR KR1020127003479A patent/KR101809024B1/ko active IP Right Grant
- 2010-06-24 EA EA201290027A patent/EA022816B1/ru not_active IP Right Cessation
- 2010-06-24 SG SG2012002010A patent/SG177609A1/en unknown
- 2010-06-24 RS RS20150326A patent/RS53987B1/en unknown
- 2010-06-24 GE GEAP201012567A patent/GEP20146056B/en unknown
- 2010-06-24 EP EP10737252.6A patent/EP2454282B1/fr active Active
- 2010-06-24 AU AU2010272944A patent/AU2010272944B2/en not_active Ceased
- 2010-06-24 MY MYPI2012000113A patent/MY188182A/en unknown
- 2010-06-24 PE PE2012000038A patent/PE20121130A1/es not_active Application Discontinuation
- 2010-06-24 DK DK10737252T patent/DK2454282T3/en active
- 2010-06-24 CN CN201080038110.7A patent/CN102574903B/zh not_active Expired - Fee Related
-
2011
- 2011-12-22 IL IL217150A patent/IL217150A0/en unknown
-
2012
- 2012-01-11 EC EC2012011593A patent/ECSP12011593A/es unknown
- 2012-02-08 MA MA34615A patent/MA33517B1/fr unknown
- 2012-11-20 HK HK12111853.9A patent/HK1171035A1/xx not_active IP Right Cessation
-
2015
- 2015-05-26 HR HRP20150557TT patent/HRP20150557T1/hr unknown
- 2015-09-02 US US14/843,047 patent/US10004786B2/en not_active Expired - Fee Related
-
2018
- 2018-05-22 US US15/985,934 patent/US20190076506A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33517B1 (fr) | Analogues acylés du glucagon | |
MA32970B1 (fr) | Analogues du glucagon | |
MA34383B1 (fr) | Analogues de glucagon | |
MA37983A1 (fr) | Analogues du glucagon | |
NZ593813A (en) | Glucagon analogues | |
MX2011006320A (es) | Analogos de glucagon. | |
MX2011006314A (es) | Analogos de glucagon. | |
ATE520714T1 (de) | Glucagonanaloga | |
MX2010005282A (es) | Anticuerpos humanizados contra tl1a. | |
MA35864B1 (fr) | Analogues du glucagon | |
WO2010008831A3 (fr) | Composés et procédés pour moduler les récepteurs couplés à la protéine g | |
WO2007011941A3 (fr) | Anticorps neutralisants anti-b7rp1 humains | |
WO2006074428A3 (fr) | Antagonistes de cxcr4 pour le traitement de troubles medicaux | |
CY1111577T1 (el) | Συνθεσεις και μεθοδοι για την αντιμετωπιση ινωτικων διαταραχων | |
EP4219522A3 (fr) | Prévention de la réduction de liaisons disulfures pendant la production recombinante de polypeptides | |
PE20140232A1 (es) | Proteinas de enlace antigeno capaz de enlazar linfopoyetina estromal timica | |
EP2604693A3 (fr) | Molécules à chaîne unique TNFSF | |
EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
BR112012019924A2 (pt) | polipeptídeos de ligação de agonista de dr5. | |
WO2008024302A8 (fr) | Composés pour le traitement de troubles prolifératifs | |
WO2008147556A3 (fr) | Ligands de récepteurs de la mélanocortine modifiés au moyen d'hydantoïne | |
WO2011044452A3 (fr) | Procédés et compositions pour l'amélioration d'une maladie auto-immune utilisant des protéines de fusion d'un anticorps anti-récepteurs des cellules dendritiques avec des séquences peptidiques | |
WO2008008224A3 (fr) | Compositions à base de récepteurs de goût acide, et procédés correspondants | |
Kelly | Urban air pollution: what is the connection between traffic and oxidative biology | |
Shirakawa | The Way to Control Particles Motion by Electric Fields |